172 related articles for article (PubMed ID: 36808829)
1. Inhibition of EZH2 exerts antitumorigenic effects in renal cell carcinoma via LATS1.
Hong SH; Hwang HJ; Son DH; Kim ES; Park SY; Yoon YE
FEBS Open Bio; 2023 Apr; 13(4):724-735. PubMed ID: 36808829
[TBL] [Abstract][Full Text] [Related]
2. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
3. Expression and clinical value of SALL4 in renal cell carcinomas.
Che J; Wu P; Wang G; Yao X; Zheng J; Guo C
Mol Med Rep; 2020 Aug; 22(2):819-827. PubMed ID: 32468053
[TBL] [Abstract][Full Text] [Related]
4. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
[TBL] [Abstract][Full Text] [Related]
5. Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma.
Ho TH; Kapur P; Eckel-Passow JE; Christie A; Joseph RW; Serie DJ; Cheville JC; Thompson RH; Homayoun F; Panwar V; Brugarolas J; Parker AS
J Clin Oncol; 2017 Nov; 35(32):3706-3713. PubMed ID: 28976794
[TBL] [Abstract][Full Text] [Related]
6. Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature.
Xu B; Abourbih S; Sircar K; Kassouf W; Mansure JJ; Aprikian A; Tanguay S; Brimo F
Arch Pathol Lab Med; 2013 Oct; 137(10):1326-36. PubMed ID: 24079759
[TBL] [Abstract][Full Text] [Related]
7. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers.
Argani P; Hicks J; De Marzo AM; Albadine R; Illei PB; Ladanyi M; Reuter VE; Netto GJ
Am J Surg Pathol; 2010 Sep; 34(9):1295-303. PubMed ID: 20679884
[TBL] [Abstract][Full Text] [Related]
8. A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data.
Zhao H; Leppert JT; Peehl DM
PLoS One; 2016; 11(1):e0146505. PubMed ID: 26814892
[TBL] [Abstract][Full Text] [Related]
9. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications.
Linehan WM; Ricketts CJ
Nat Rev Urol; 2019 Sep; 16(9):539-552. PubMed ID: 31278395
[TBL] [Abstract][Full Text] [Related]
10. Methylation‑associated inactivation of LATS1 and its effect on demethylation or overexpression on YAP and cell biological function in human renal cell carcinoma.
Chen KH; He J; Wang DL; Cao JJ; Li MC; Zhao XM; Sheng X; Li WB; Liu WJ
Int J Oncol; 2014 Dec; 45(6):2511-21. PubMed ID: 25270913
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of the YAP1 oncogene in clear cell renal cell carcinoma is associated with poor outcome.
Rybarczyk A; Klacz J; Wronska A; Matuszewski M; Kmiec Z; Wierzbicki PM
Oncol Rep; 2017 Jul; 38(1):427-439. PubMed ID: 28504812
[TBL] [Abstract][Full Text] [Related]
12. A pan-kidney cancer study identifies subtype specific perturbations on pathways with potential drivers in renal cell carcinoma.
Zhan X; Liu Y; Yu CY; Wang TF; Zhang J; Ni D; Huang K
BMC Med Genomics; 2020 Dec; 13(Suppl 11):190. PubMed ID: 33371886
[TBL] [Abstract][Full Text] [Related]
13. EZH2 enhances the invasive capability of renal cell carcinoma cells via activation of STAT3.
Zhang D; Yang XJ; Luo QD; Fu DL; Li HL; Li HC; Zhang P; Chong T
Mol Med Rep; 2018 Mar; 17(3):3621-3626. PubMed ID: 29286132
[TBL] [Abstract][Full Text] [Related]
14. The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells.
Wagener N; Holland D; Bulkescher J; Crnković-Mertens I; Hoppe-Seyler K; Zentgraf H; Pritsch M; Buse S; Pfitzenmaier J; Haferkamp A; Hohenfellner M; Hoppe-Seyler F
Int J Cancer; 2008 Oct; 123(7):1545-50. PubMed ID: 18623083
[TBL] [Abstract][Full Text] [Related]
15. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.
Liu L; Xu Z; Zhong L; Wang H; Jiang S; Long Q; Xu J; Guo J
BJU Int; 2016 Feb; 117(2):351-62. PubMed ID: 24612432
[TBL] [Abstract][Full Text] [Related]
16. [Expressions of EZH2 and RUNX3 in renal cell carcinoma and their clinical significance].
Wang G; Qin W; Zheng J; Wei M; Zhou X; Wang H; Wen W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):82-4, 88. PubMed ID: 23294722
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of Hippo signalling activity in different histopathologic subtypes of renal cell carcinoma.
Duong NX; Le MK; Kondo T; Mitsui T
J Cell Mol Med; 2023 Jan; 27(1):66-75. PubMed ID: 36478130
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation profiling distinguishes histological subtypes of renal cell carcinoma.
Slater AA; Alokail M; Gentle D; Yao M; Kovacs G; Maher ER; Latif F
Epigenetics; 2013 Mar; 8(3):252-67. PubMed ID: 23428843
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.
Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson EO; Lam TB; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Dabestani S; Bex A
Eur Urol Oncol; 2021 Jun; 4(3):473-482. PubMed ID: 33109495
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.
Wang Y; Chen Y; Geng H; Qi C; Liu Y; Yue D
Tumour Biol; 2015 Sep; 36(9):7159-66. PubMed ID: 25877750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]